This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

The Effects of Newer Antidepressants on Low-Density Lipoprotein Cholesterol Levels

Jean-Michel Le Mellédo, MD, Maria del Pilar Castillo Abadia, MD Steve Newman, MD, PhD Darrin Bailey, MD, PhD, Ross Tsuyuki, BSc(Pharm), PharmD, MSc, Gabor Gyenes, MD, PhD

Published: July 1, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Nicholas et al.1 must be commended for investigating atopic of major clinical importance, i.e., the effects of the newer antidepressants, such as mirtazapine, on serum levels of lowdensity lipoprotein cholesterol (LDL-C). Indeed, LDL-C levels are considered as an important predictor of cardiovascular events.2 The authors showed a statistically nonsignificant increase of 3% in LDL-C in healthy controls after 4 weeks of mirtazapine treatment compared with placebo treatment and concluded that mirtazapine did not increase LDL-C levels.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: